Sulfonadyn-based dynamin I-specific inhibitors and epilepsy

癫痫影响1%的人，但30%的人对抗癫痫药物（AED）没有反应。传统的药物发现无法改善这种情况。我们的团队发现发动蛋白是更好的AED设计的新靶点，我们的铅磺丁可以减少动物的癫痫发作。我们将设计更好的磺胺类药物，通过设计药物远离神经元外的作用，最终可以用于临床试验。如果成功，这将加速新的AED开发，副作用更少。

Epilepsy affects 1% of people, yet 30% do not respond to anti-epileptic drugs (AEDs). Traditional drug discovery fails to improve this situation. Our team discovered dynamin as a new target for better AED design and our lead sulphonadyns reduces seizures in animals. We will design better sulfonadyns that can ultimately be used for clinical trials by designing the drugs away from its actions outside of neurons. If successful, this will accelerate new AED development with less side-effects.